309 related articles for article (PubMed ID: 25752159)
1. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
2. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
3. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
Duguet C; Ferry A
Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
[No Abstract] [Full Text] [Related]
4. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
5. HHS defends expanded 340B drug discounts.
Lee J
Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
[No Abstract] [Full Text] [Related]
6. Jumpstarting research into neglected diseases.
Leslie M
Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
[TBL] [Abstract][Full Text] [Related]
7. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
8. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
9. Reducing the cost of rare disease drugs.
Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
[No Abstract] [Full Text] [Related]
10. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
11. Reforming the Orphan Drug Act for the 21st Century.
Sarpatwari A; Kesselheim AS
N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
[No Abstract] [Full Text] [Related]
12. Adoption agents.
Wapner J
Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
[No Abstract] [Full Text] [Related]
13. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
14. The orphan drug backlash.
Maeder T
Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333
[No Abstract] [Full Text] [Related]
15. The balancing act of orphan drug pricing.
The Lancet
Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
[No Abstract] [Full Text] [Related]
16. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
17. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
18. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
19. Open letter to prime minister David Cameron and health secretary Andrew Lansley.
Nicholl DJ; Hilton-Jones D; Palace J; Richmond S; Finlayson S; Winer J; Weir A; Maddison P; Fletcher N; Sussman J; Silver N; Nixon J; Kullmann D; Embleton N; Beeson D; Farrugia ME; Hill M; McDermott C; Llewelyn G; Leonard J; Morris M
BMJ; 2010 Nov; 341():c6466. PubMed ID: 21081599
[No Abstract] [Full Text] [Related]
20. Companies look for profit in orphan drugs.
Thompson CA
Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
[No Abstract] [Full Text] [Related]
[Next] [New Search]